According to the China Securities News, Wind data shows that as of 22:50 on August 30, a total of 508 A-share listed pharmaceutical companies had disclosed their 2026 semi-annual reports, and 191 companies achieved a year-on-year increase in net profit to the mother. Of these, 40 had a year-on-year increase in net profit to mother. Analysts believe that in the context of the new cycle of the pharmaceutical boom, the domestic innovative drug industry chain is rising at an accelerated pace. In recent years, the country has taken many measures to support the development of innovative drugs throughout the entire chain. Combined with multi-dimensional advantages such as talent reserves and R&D efficiency, China's innovative pharmaceutical companies have gradually gained global competitiveness. At the same time, some multinational pharmaceutical companies are facing the “patent cliff” dilemma. Demand for external procurement and expansion of innovation pipelines is increasing day by day. Domestic innovative pharmaceutical companies are following the trend and innovate overseas in the form of overseas licensing and other forms of business expansion. The field is expected to begin a new boom cycle.

According to the China Securities News, Wind data shows that as of 22:50 on August 30, a total of 508 A-share listed pharmaceutical companies had disclosed their 2026 semi-annual reports, and 191 companies achieved a year-on-year increase in net profit to the mother. Of these, 40 had a year-on-year increase in net profit to mother. Analysts believe that in the context of the new cycle of the pharmaceutical boom, the domestic innovative drug industry chain is rising at an accelerated pace. In recent years, the country has taken many measures to support the development of innovative drugs throughout the entire chain. Combined with multi-dimensional advantages such as talent reserves and R&D efficiency, China's innovative pharmaceutical companies have gradually gained global competitiveness. At the same time, some multinational pharmaceutical companies are facing the “patent cliff” dilemma. Demand for external procurement and expansion of innovation pipelines is increasing day by day. Domestic innovative pharmaceutical companies are following the trend and innovate overseas in the form of overseas licensing and other forms of business expansion. The field is expected to begin a new boom cycle.